Ekso Bionics Holdings, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Lease Obligations

Lease Obligations

3 Months Ended

Mar. 31, 2022

The Company maintains a five-year operating lease agreement for its headquarters and manufacturing facility in Richmond, California (the "Richmond Lease") which expires in May 2022, with no further options to extend or terminate. The lease includes non-lease components (i.e. common area maintenance costs) that are paid separately from rent based on actual costs incurred.

The Company maintains a five-year operating lease agreement for its European operations office in Hamburg, Germany, which expires in July 2022. In February 2022, the Company executed a new lease agreement for a replacement office in Hamburg, Germany commencing May 1, 2022 and expiring June 30, 2025 with an option to renew for one five-year period. Since this operating lease commences after March 31, 2022, the lease payments are not recognized in lease liabilities and corresponding right-of-use assets on the balance sheet as of March 31, 2022.

The Company’s future lease payments as of March 31, 2022, which are presented as lease liabilities on the Company’s condensed consolidated balance sheets are as follows:


Period	Operating Leases
Remainder of 2022	$	98
2023	—
Total lease payments	98
Less: imputed interest	(1)
Present value of lease liabilities	$	97

Weighted-average remaining lease term (in years)	0.2
Weighted-average discount rate	10.5		%

Lease expense under the Company’s operating leases was $142 and $132 for the three months ended March 31, 2022 and 2021, respectively.